Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Employees - 8, CEO - Gerald T. Proehl, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -23.58, Piotroski Score(max is 10): 1, Working Capital: $3960102, Total Assets: $5071410, Retained Earnings: $-71372007, EBIT: -8847607, Total Liabilities: $1111308, Revenue: $0

- Current Price $ - Analyst Target Price $